For many medical innovators, regulatory approval feels like the major hurdle. The data is strong, clinicians are engaged, and the therapy is ready for use. It’s tempting to think:
Yes! We’ve made it!
Yet in Australia, approval often marks the beginning of a new challenge: navigating a funding system that moves at a measured and cautious pace.
Delays aren’t unusual. Reimbursements for new medicines are notoriously slow compared to other countries, with Medicines Australia citing on average it takes 466 days for a new drug to Listings for new therapy to be funded, for medical devices it’s even longer. Reimbursement committees are balancing competing priorities, budgets are fixed, and the queue is long. Without clear signals that a therapy requires timely attention, it can drift into the background while other issues move ahead.
Across our work with MedTech, pharmaceutical, diagnostics, and biopharma companies, three practices consistently help organisations keep their therapy visible and progressing.
Clinical data demonstrates safety and efficacy, but decision-makers often respond most strongly to the practical consequences of waiting for example:
When the cost of inaction is clear, the case for timely review becomes easier for policymakers to recognise and prioritise.
Funding committees evaluate submissions in detail, but political leaders absorb information differently. They look for meaning, relevance, and lived experience.
A therapy becomes easier to champion when its impact is expressed through:
These stories don’t replace the science, they help decision-makers understand why the science matters.
Even strong submissions can fade from view when the system is managing many simultaneous demands. Staying visible helps prevent that drift.
Effective companies keep their therapy present through ongoing engagement with stakeholders who influence the journey, including:
When these voices remain active, policymakers can see that the issue continues to hold relevance across the sector and within the community.
Visibility ensures the therapy stays on the agenda at the moments when decisions are being shaped.
Every month of delay has tangible consequences for patients, for clinicians, and for the broader health system. While Australia’s processes are intentionally thorough, they respond to clear signals of impact, relevance, and urgency.
Therapies move forward more consistently when companies:
These efforts help ensure that an innovation remains in focus, rather than waiting passively in a system designed to move slowly.
London Agency works with organisations across the sector to help them create this kind of sustained momentum: aligning evidence, engagement, and visibility in ways that support timely progress.
If you’d like to strengthen your therapy’s position within the funding landscape, our team can help you navigate the journey with clarity and confidence.
